Literature DB >> 18022380

A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations.

Shi-Shan Mao1, Jillian DiMuzio, Carolyn McHale, Christine Burlein, David Olsen, Steven S Carroll.   

Abstract

The hepatitis C virus (HCV) nonstructural protein 3 (NS3) with its cofactor NS4A is a pivotal enzyme for the replication of HCV. Inhibition of NS3-4A protease activity has been validated as an antiviral target in clinical studies of inhibitors of the enzyme. We have developed a sensitive time-resolved fluorescence (TRF) assay capable of detecting very low NS3-4A concentrations. A depsipeptide substrate is used that contains a europium-cryptate moiety and an efficient quenching group, QSY-7. The TRF assay is at least 30-fold more sensitive than a fluorescence energy transfer (FRET) assay and allows evaluation of NS3 protease inhibitors in reactions catalyzed by low enzyme concentrations (30 pM). Use of low enzyme concentrations allows for accurate measurement of inhibition by compounds with subnanomolar inhibition constants. The inhibitory potency of the potent protease inhibitor, BILN-2061, is significantly greater than previously reported. The ability to accurately determine inhibitory potency in reactions with low picomolar concentrations of NS3-4A is crucially important to allow valid comparisons between potent inhibitors. Studies of the interaction of NS3 with its NS4A cofactor at low enzyme concentration also reveal that the protease activity is salt dependent. This salt dependence of the enzyme activity is not present when high enzyme concentrations are used in the FRET assay.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022380     DOI: 10.1016/j.ab.2007.10.041

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

Authors:  Michael T Rudd; John A McCauley; John W Butcher; Joseph J Romano; Charles J McIntyre; Kevin T Nguyen; Kevin F Gilbert; Kimberly J Bush; M Katharine Holloway; John Swestock; Bang-Lin Wan; Steven S Carroll; Jillian M DiMuzio; Donald J Graham; Steven W Ludmerer; Mark W Stahlhut; Christine M Fandozzi; Nicole Trainor; David B Olsen; Joseph P Vacca; Nigel J Liverton
Journal:  ACS Med Chem Lett       Date:  2011-01-12       Impact factor: 4.345

2.  MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Authors:  Vincenzo Summa; Steven W Ludmerer; John A McCauley; Christine Fandozzi; Christine Burlein; Giuliano Claudio; Paul J Coleman; Jillian M Dimuzio; Marco Ferrara; Marcello Di Filippo; Adam T Gates; Donald J Graham; Steven Harper; Daria J Hazuda; Qian Huang; Carolyn McHale; Edith Monteagudo; Vincenzo Pucci; Michael Rowley; Michael T Rudd; Aileen Soriano; Mark W Stahlhut; Joseph P Vacca; David B Olsen; Nigel J Liverton; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.

Authors:  Zhuyan Guo; Stuart Black; Yuan Hu; Patricia McMonagle; Paul Ingravallo; Robert Chase; Stephanie Curry; Ernest Asante-Appiah
Journal:  J Biol Chem       Date:  2017-02-21       Impact factor: 5.157

4.  Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.

Authors:  Xuemei Yu; Bruno Sainz; Susan L Uprichard
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

5.  MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.

Authors:  Nigel J Liverton; Steven S Carroll; Jillian Dimuzio; Christine Fandozzi; Donald J Graham; Daria Hazuda; M Katherine Holloway; Steven W Ludmerer; John A McCauley; Charles J McIntyre; David B Olsen; Michael T Rudd; Mark Stahlhut; Joseph P Vacca
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

6.  Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells.

Authors:  Rosario Sabariegos; Fernando Picazo; Beatriz Domingo; Sandra Franco; Miguel-Angel Martinez; Juan Llopis
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

7.  Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase.

Authors:  Rudolf K F Beran; Anna Marie Pyle
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

8.  Substrate specificity of Tulane virus protease.

Authors:  Chao Wei; Jarek Meller; Xi Jiang
Journal:  Virology       Date:  2012-11-08       Impact factor: 3.616

9.  Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes.

Authors:  Rodney K Lyn; Ragunath Singaravelu; Stacia Kargman; Shifawn O'Hara; Helen Chan; Renata Oballa; Zheng Huang; Daniel M Jones; Andrew Ridsdale; Rodney S Russell; Anthony W Partridge; John Paul Pezacki
Journal:  Sci Rep       Date:  2014-04-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.